Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 643 matching drugs for PIK3R1 — including drugs targeting any of its 112 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 Direct 1
enzastaurin, lomustine PIK3R1 Direct 1
enzastaurin, temozolomide, radiation therapy PIK3R1 Direct 1
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CTLA4 SSL via CTLA4 4
nivolumab, ipilimumab CTLA4 SSL via CTLA4 4
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) CTLA4 SSL via CTLA4 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BTK SSL via BTK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK6 SSL via CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR3 SSL via FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR4 SSL via FGFR4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib WEE1 SSL via WEE1 3
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab CTLA4 SSL via CTLA4 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR3 SSL via FGFR3 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR4 SSL via FGFR4 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone RXRB SSL via RXRB 3
pembrolizumab, belzutifan, lenvatinib FGFR3 SSL via FGFR3 3
pembrolizumab, belzutifan, lenvatinib FGFR4 SSL via FGFR4 3
abemaciclib CDK6 SSL via CDK6 yes 2
adavosertib, radiation therapy WEE1 SSL via WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR3 SSL via FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
alvocidib, paclitaxel CDK6 SSL via CDK6 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
bbi-355, erlotinib, futibatinib FGFR3 SSL via FGFR3 2
bbi-355, erlotinib, futibatinib FGFR4 SSL via FGFR4 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BTK SSL via BTK 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK6 SSL via CDK6 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
bms-986207, nivolumab, ipilimumab CTLA4 SSL via CTLA4 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel CTLA4 SSL via CTLA4 2
durvalumab, tremelimumab, sbrt CTLA4 SSL via CTLA4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK6 SSL via CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
everolimus MTOR SSL via MTOR yes 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR3 SSL via FGFR3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR4 SSL via FGFR4 2
ibrutinib BTK SSL via BTK yes 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
ipilimumab CTLA4 SSL via CTLA4 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
lenvatinib, pembrolizumab FGFR3 SSL via FGFR3 2
lenvatinib, pembrolizumab FGFR4 SSL via FGFR4 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR3 SSL via FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR4 SSL via FGFR4 2
ly3022855, durvalumab, tremelimumab CTLA4 SSL via CTLA4 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR3 SSL via FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR4 SSL via FGFR4 2
motexafin gadolinium, radiation therapy RRM2 SSL via RRM2 2
nintedanib FGFR3 SSL via FGFR3 yes 2
nintedanib, pembrolizumab FGFR3 SSL via FGFR3 2
nivolumab, ipilimumab, cobimetinib CTLA4 SSL via CTLA4 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
olaparib PARP3 SSL via PARP3 2
palbociclib CDK6 SSL via CDK6 yes 2
pazopanib FGFR3 SSL via FGFR3 yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, guadecitabine, mocetinostat HDAC3 SSL via HDAC3 2
pembrolizumab, lenvatinib FGFR3 SSL via FGFR3 2
pembrolizumab, lenvatinib FGFR4 SSL via FGFR4 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR3 SSL via FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR4 SSL via FGFR4 2
pembrolizumab, sonidegib SMO SSL via SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR3 SSL via FGFR3 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR4 SSL via FGFR4 2
pharmacological study, romidepsin ABCC1 SSL via ABCC1 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
pharmacological study, romidepsin HDAC4 SSL via HDAC4 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR3 SSL via FGFR3 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
selumetinib, medi4736, tremelimumab CTLA4 SSL via CTLA4 2
selumetinib, medi4736, tremelimumab MAP2K1 SSL via MAP2K1 2
stereotactic body radiotherapy, ipilimumab, nivolumab, pembrolizumab or atezolizumab CTLA4 SSL via CTLA4 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
trabectedin, ipilimumab, nivolumab CTLA4 SSL via CTLA4 2
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PARP3 SSL via PARP3 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.